Chemotherapy and quality of life in NSCLC PS 2 patients

Acta Oncologica

Volumn 48, Issue 7, 2009, Pages 1019-1025

  Helbekkmo, Nina ^a   Strøm, Hans H ^a   Sundstrøm, Stein H ^b   Aasebø, Ulf ^c   Von Plessen, Christian ^d   Bremnes, Roy M ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; GEMCITABINE; NAVELBINE;

ADULT; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COGNITION; CONTROLLED STUDY; DYSPNEA; FATIGUE; FEMALE; HEALTH STATUS; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SLEEP DISORDER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEMALE; HUMANS; KARNOFSKY PERFORMANCE STATUS; LIFE EXPECTANCY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT COMPLIANCE; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME; VINBLASTINE;

EID: 70350072837     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860902795240     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Kelly K. Challenges in defining and identifying patients with non-small cell lung cancer and poor performance status. Semin Oncol 2004;31:3-7.
3. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: Univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 1995;13:1221-30.
4. Sweeney CJ, Zhu J, Sandler AB, Schiller J, Belani CP, Langer C, et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: A Phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer 2001;92:2639-47.
5. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980;65:25-32.
6. Fallowfield LJ, Harper P. Health-related quality of life in patients undergoing drug therapy for advanced non-smallcell lung cancer. Lung Cancer 2005;48:365-77.
7. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. J Clin Oncol 1996;14:671-679
8. Gridelli C, Ardizzoni A, Le CT, Manegold C, Perrone F, Thatcher N, et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: Results of an European Experts Panel. Ann Oncol 2004;15: 419-426
9. National Institute for Clinical Excellence. Clinical Guideline 24, Lung cancer: the diagnosis and treatment of lung cancer. 2005 (Report).
10. Bottomley A, Efficace F, Thomas R, Vanvoorden V, Ahmedzai SH. Health-related quality of life in non-smallcell lung cancer: Methodologic issues in randomized controlled trials. J Clin Oncol 2003;21:2982-92.
11. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 2004;22:330-53.
12. Billingham LJ, Cullen MH. The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer. Ann Oncol 2001;12:1671-5.
13. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8. (Pubitemid 34438899)
14. Soria JC, Brisgand D, Le Chevalier T. Do all patients with advanced non-small-cell lung cancer benefit from cisplatinbased combination therapy? Ann Oncol 2001;12:1667-70.
15. Lilenbaum RC, Herndon JE, List MA, Desch C, Watson DM, Miller AA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The cancer and leukemia group B (study 9730). J Clin Oncol 2005;23:190-6.
16. Helbekkmo N, Aasebo U, Sundstrom SH, von Plessen C, Brunsvig PF, Bremnes RM. Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy. Lung Cancer 2008;62:253-60.
17. Helbekkmo N, Sundstrom SH, Aasebo U, Brunsvig PF, von Plessen C, Hjelde HH, et al. Vinorelbinecarboplatin vs gemcitabinecarboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 2007; 97:283-9.
18. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
19. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.
20. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: A modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 1994;30A:635-42.
21. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-30. Scoring Manual 3rd ed. 2001.
22. Fairclough DL. Summary measures and statistics for comparison of quality of life in a clinical trial of cancer therapy. Stat Med 1997;16:1197-209.
23. Fayers PM, Machin D. Quality of Life. Assessment, analysis and interpretetation. 1st ed. Chichester: John Wiley and Sons Ltd.; 2000.
24. Osoba D, Bezjak A, Brundage M, Zee B, Tu D, Pater J. Analysis and interpretation of health-related quality-of-life data from clinical trials: Basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur Cancer 2005;41:280-7.
25. Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life. J Clin Oncol 1999;17: 3188-3194
26. Lilenbaum R, Axelrod R, Thomas S, Dowlati A, Seigel L, Albert D, et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced nonsmall- cell lung cancer and a performance status of 2. J Clin Oncol 2008;26:863-9.
27. Bernhard J, Cella DF, Coates AS, Fallowfield L, Ganz PA, Moinpour CM, et al. Missing quality of life data in cancer clinical trials: Serious problems and challenges. Stat Med 1998;17:517-32.
28. Herndon JE, Fleishman S, Kosty MP, Green MR. A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931. Control Clin Trials 1997;18:286-300.
29. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med 2007;357:2189-94.
30. Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999;17:1654-63. (Pubitemid 29269233)
31. Tishelman C, Degner LF, Rudman A, Bertilsson K, Bond R, Broberger E, et al. Symptoms in patients with lung carcinoma: Distinguishing distress from intensity. Cancer 2005;104:2013-21.